Elizabeth A. Raetz, MD / Rachel Rau, MD - Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds

Go online to PeerView.com/ZBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert faculty panel focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric acute lymphoblastic leukemia (ALL) therapy by pairing a sample case scenario with a short lecture designed to illustrate the tactics and techniques for addressing hypersensitivity and effectively utilizing available asparaginase options. Upon completion of this accredited CE activity, participants should be better able to: Describe the clinical implications of Escherichia coli asparaginase hypersensitivity and asparaginase discontinuation in pediatric acute lymphoblastic leukemia (ALL), Summarize evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations, as a component of multiagent chemotherapy for pediatric ALL, Develop protocols for the management of E coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.